Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4442 | convalescent plasma application to SARS-CoV-2 infected patients Wiki | 1.00 |
| drug2932 | Placebo 250 cc 24 hours continuous infusion for 15 days Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000075902 | Clinical Deterioration NIH | 0.71 |
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Protection of endothelial dysfunction by intravenous infusion of Defibrotide (Defitelio), expected to decrease inflammation and expression of adhesion molecules in the endothelium, leukocyte tissue infiltration and epithelial destruction, and to promote immune tolerance through a change in the Cytokine balance, which is decisive in preventing multiorgan failure and death in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification
Description: All cause mortality
Measure: 1. Mortality rate Time: : up to 30 daysDescription: Decrease the rate of grades 4-5 patients requiring mechanical ventilation.
Measure: Clinical improvement by WHO Time: 7, 15, 30 and 60 DayDescription: Decrease ventilation days in grade 6 patients
Measure: Clinical improvement by WHO Time: 7, 15, 30 and 60 DayDescription: Decrease the rate of grades 4-5 patients requiring mechanical ventilation.
Measure: Clinical improvement by NEWS2 scales Time: 7, 15, 30 and 60 DayDescription: Decrease ventilation days in grade 6 patients
Measure: Clinical improvement by NEWS2 scales Time: 7, 15, 30 and 60 DayDescription: Decrease of IL-6 levels with respect to the basal ones > 50%.
Measure: Biologic response Time: 7, 15, 30 and 60 DayDescription: Absolute lymphocytes count: 50% increase with respect to the baseline
Measure: Biologic response Time: 7, 15, 30 and 60 DayDescription: Normal D-dimer (DD) or decrease of 50% with respect to the baseline
Measure: Biologic response Time: 7, 15, 30 and 60 DayDescription: Normal CRP or decrease of 50% with respect to the baseline
Measure: Biologic response Time: 7, 15, 30 and 60 DayDescription: Normal LDH or decrease of 50% with respect to the baseline
Measure: Biologic response Time: 7, 15, 30 and 60 DayDescription: Normal CPK or decrease of 50% with respect to the baseline
Measure: Biologic response Time: 7, 15, 30 and 60 DayDescription: Normal Ferritin or decrease of 50% with respect to the baseline
Measure: Biologic response Time: 7, 15, 30 and 60 DayDescription: Improvement of radiological images by conventional radiology
Measure: Radiological response Time: 7, 15, 30 and 60 DayDescription: improve the knowledge of the disease at the inclusion of the patients
Measure: Collection and storage of biological samples Time: 15,30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports